Mar 1, 2023
Existing Board member Jerry He to replace David Green as Chairman and Chief Executive Officer; David Green to remain on the Board and support transition HOLLISTON, Mass., March 1, 2023 /PRNewswire/ --
Jan 12, 2023
Biostage removes Interim qualification from Mr. Green's title, making him Chief Executive Officer. HOLLISTON, Mass., Jan. 12, 2023 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the...
Dec 28, 2022Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer
IQVIA was selected because of its dedicated gastrointestinal team and depth of experience in running cell-therapy clinical trials. HOLLISTON, Mass., Dec. 28, 2022 /PRNewswire/ -- Biostage, Inc....
Dec 23, 2022
Biostage expects to initiate patient recruitment in its first clinical trial in early 2023 HOLLISTON, Mass., Dec. 23, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the...
Nov 14, 2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo...